ATE404564T1 - Diazepinoindolderivate als kinaseinhibitoren - Google Patents

Diazepinoindolderivate als kinaseinhibitoren

Info

Publication number
ATE404564T1
ATE404564T1 AT04700145T AT04700145T ATE404564T1 AT E404564 T1 ATE404564 T1 AT E404564T1 AT 04700145 T AT04700145 T AT 04700145T AT 04700145 T AT04700145 T AT 04700145T AT E404564 T1 ATE404564 T1 AT E404564T1
Authority
AT
Austria
Prior art keywords
diazepinoindol
derivatives
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
AT04700145T
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael Bennett
Yuanjin Eugene Rui
Fen Wang
Suzanne BENEDICT
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE404564T1 publication Critical patent/ATE404564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04700145T 2003-01-09 2004-01-05 Diazepinoindolderivate als kinaseinhibitoren ATE404564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
ATE404564T1 true ATE404564T1 (de) 2008-08-15

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700145T ATE404564T1 (de) 2003-01-09 2004-01-05 Diazepinoindolderivate als kinaseinhibitoren

Country Status (34)

Country Link
US (3) US6967198B2 (de)
EP (2) EP1947102A1 (de)
JP (1) JP3990718B2 (de)
KR (1) KR100697746B1 (de)
CN (1) CN1759118B (de)
AP (1) AP2048A (de)
AT (1) ATE404564T1 (de)
AU (1) AU2004203977B2 (de)
BR (1) BRPI0406701A (de)
CA (1) CA2512683C (de)
CR (1) CR7899A (de)
CY (1) CY1108408T1 (de)
DE (1) DE602004015724D1 (de)
DK (1) DK1585749T3 (de)
EA (1) EA009337B1 (de)
EC (1) ECSP055911A (de)
ES (1) ES2309484T3 (de)
GE (1) GEP20084367B (de)
HR (1) HRP20050624A2 (de)
IL (1) IL169082A (de)
IS (1) IS7884A (de)
MA (1) MA27703A1 (de)
MX (1) MXPA05007352A (de)
NO (1) NO20053775L (de)
NZ (1) NZ540638A (de)
OA (1) OA13017A (de)
PL (1) PL378372A1 (de)
PT (1) PT1585749E (de)
RS (1) RS20050522A (de)
SI (1) SI1585749T1 (de)
TN (1) TNSN05176A1 (de)
UA (1) UA80733C2 (de)
WO (1) WO2004063198A1 (de)
ZA (1) ZA200504674B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
DK1585749T3 (da) * 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer
PL1853721T3 (pl) * 2005-02-18 2010-08-31 Astrazeneca Ab Sposób określania wrażliwości na inhibitory CHK1
WO2006105262A1 (en) 2005-03-29 2006-10-05 Icos Corporation HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
JP2009505989A (ja) * 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＶＥＧＦによって活性化されるＦａｓリガンド
EP1942193A4 (de) 2005-08-25 2010-10-27 Ube Industries VERFAHREN ZUR HERSTELLUNG OPTISCH AKTIVER (S ODER R)-a- AMINOSÄURE ODER EINES OPTISCH AKTIVEN (S ODER R) -a-AMINOSÄUREESTERS
EP1916896A4 (de) * 2005-08-26 2010-08-11 Univ California Nichtsteroid-antiandrogene
RU2409361C2 (ru) * 2006-04-04 2011-01-20 Пфайзер Продактс Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ
CA2648369A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EP2086644A2 (de) * 2006-11-17 2009-08-12 Schering Corporation Kombination aus einem hemmer der dna-polymerase-alpha und einem hemmer der checkpointkinase zur behandlung von proliferativen erkrankungen
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
WO2010040527A1 (en) * 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2793882A4 (de) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc Verabreichung von hypoxie-aktivierten prodrugs in kombination mit chk1-inhibitoren zur behandlung von krebs
NZ626937A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
RS56616B1 (sr) * 2011-12-31 2018-02-28 Beigene Ltd Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
CN107922425B (zh) * 2015-08-25 2021-06-01 百济神州有限公司 制备parp抑制剂、结晶形式的方法及其用途
EP3355926B1 (de) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Kombination von dna-schädigenden mitteln und atr-inhibitoren zur verwendung in einem verfahren zur behandlung von krebs
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
BR112020005489A2 (pt) * 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
EP3461480A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
JP2022523028A (ja) * 2019-01-25 2022-04-21 ヌメディー， インコーポレイテッド 特発性肺線維症を処置するための方法
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
ES3014705T3 (en) 2019-11-29 2025-04-24 Novaonco Js Therapeutics Co Ltd Diazaindole derivative and use thereof as chk1 inhibitor
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
EP1144609B1 (de) 1999-08-27 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
JP4610828B2 (ja) 1999-09-22 2011-01-12 株式会社 キャンバス Ｇ２期細胞周期停止の阻害、およびｄｎａ損傷剤に対する細胞感作のための組成物および方法
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
DE60142921D1 (de) * 2000-12-01 2010-10-07 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
DK1585749T3 (da) * 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer

Also Published As

Publication number Publication date
CY1108408T1 (el) 2014-02-12
MA27703A1 (fr) 2006-01-02
RS20050522A (sr) 2007-12-31
ES2309484T3 (es) 2008-12-16
US20060004052A1 (en) 2006-01-05
KR20050092397A (ko) 2005-09-21
BRPI0406701A (pt) 2005-12-20
EA009337B1 (ru) 2007-12-28
SI1585749T1 (sl) 2008-10-31
CR7899A (es) 2005-08-05
OA13017A (en) 2006-11-10
WO2004063198A1 (en) 2004-07-29
US7462713B2 (en) 2008-12-09
NO20053775D0 (no) 2005-08-08
GEP20084367B (en) 2008-05-13
CN1759118A (zh) 2006-04-12
CN1759118B (zh) 2010-12-08
US20050075499A1 (en) 2005-04-07
NO20053775L (no) 2005-09-16
US7132533B2 (en) 2006-11-07
NZ540638A (en) 2007-12-21
EA200500893A1 (ru) 2006-02-24
IS7884A (is) 2005-06-09
US6967198B2 (en) 2005-11-22
JP3990718B2 (ja) 2007-10-17
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (de) 2008-08-13
JP2006516274A (ja) 2006-06-29
AU2004203977B2 (en) 2010-06-17
HK1086257A1 (en) 2006-09-15
TNSN05176A1 (fr) 2007-06-11
MXPA05007352A (es) 2006-02-17
IL169082A (en) 2011-02-28
ZA200504674B (en) 2006-07-26
AP2048A (en) 2009-09-24
HRP20050624A2 (en) 2006-02-28
ECSP055911A (es) 2005-11-22
CA2512683A1 (en) 2004-07-29
US20070135415A1 (en) 2007-06-14
EP1947102A1 (de) 2008-07-23
UA80733C2 (en) 2007-10-25
DK1585749T3 (da) 2008-09-22
EP1585749A1 (de) 2005-10-19
DE602004015724D1 (de) 2008-09-25
KR100697746B1 (ko) 2007-03-22
PT1585749E (pt) 2008-10-23
CA2512683C (en) 2010-03-16
AP2005003353A0 (en) 2005-09-30
PL378372A1 (pl) 2006-04-03

Similar Documents

Publication Publication Date Title
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE388148T1 (de) Chinolinderivate als phosphodiesterase inhibitoren
IS7599A (is) Heterósýklískir kínasatálmar
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1585749

Country of ref document: EP

REN Ceased due to non-payment of the annual fee